Library Item - Page 34 of 792 Posts on Medivizor
Navigation Menu

Library Item Posts on Medivizor

Evaluating therapies after CAR-T Cell treatment in patients with relapsed and refractory ALL

Evaluating therapies after CAR-T Cell treatment in patients with relapsed and refractory ALL

Posted by on Feb 6, 2022 in Leukemia | 0 comments

In a nutshell The study aimed to investigate if allogeneic hematopoietic stem cell transplant (alloHSCT) was a suitable treatment strategy for patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) after chimeric antigen receptor (CAR) T-cell therapy.   This study concluded that this was a suitable treatment...

Read More

Treating chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab and high-dose methylprednisolone

Treating chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab and high-dose methylprednisolone

Posted by on Feb 6, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate using rituximab (Rituxan) and high-dose methylprednisolone (HDMP; Medrol) as a treatment for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).   This study concluded that this treatment is a good option for elderly and frail patients and can work as a bridge to...

Read More

Treating chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab and high-dose methylprednisolone

Treating chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab and high-dose methylprednisolone

Posted by on Feb 6, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate using rituximab (Rituxan) and high-dose methylprednisolone (HDMP; Medrol) as a treatment for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). This study concluded that this treatment is a good option for elderly and frail patients and can work as a bridge to other lines of treatment....

Read More

Can osimertinib be used as first-line therapy in older patients with EGFR-mutated NSCLC?

Can osimertinib be used as first-line therapy in older patients with EGFR-mutated NSCLC?

Posted by on Jan 30, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of osimertinib (Tagrisso) as first-line therapy for older patients above 75 years with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). The data showed that osimertinib as first-line therapy is effective in these patients. However, osimertinib was...

Read More

Evaluating the effects of enzalutamide on the health-related quality of life in patients with metastatic hormone-sensitive prostate cancer.

Evaluating the effects of enzalutamide on the health-related quality of life in patients with metastatic hormone-sensitive prostate cancer.

Posted by on Jan 30, 2022 in Prostate cancer | 0 comments

In a nutshell This study reported the long-term effects on the health-related quality of life (HR-QoL) of enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that enzalutamide preserved the overall health and quality of life in these...

Read More

Is yoga-based cardiac rehabilitation beneficial for patients with coronary artery disease?

Is yoga-based cardiac rehabilitation beneficial for patients with coronary artery disease?

Posted by on Jan 30, 2022 in Coronary artery disease | 0 comments

In a nutshell This study evaluated if yoga-based cardiac rehabilitation leads to reduced heart-related risk factors in patients with coronary artery disease (CAD) compared to standard care. The data showed that the addition of yoga to standard care showed overall improvements in the cardiac health and quality of life of these patients. Some...

Read More

Evaluating the long-term outcome of using gonadotropin-releasing hormone agonist during chemotherapy to preserve ovarian function in premenopausal patients with early-stage breast cancer.

Evaluating the long-term outcome of using gonadotropin-releasing hormone agonist during chemotherapy to preserve ovarian function in premenopausal patients with early-stage breast cancer.

Posted by on Jan 30, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the long-term outcomes of using gonadotropin-releasing hormone (GnRH) agonist during chemotherapy to preserve ovarian function in premenopausal patients with early-stage breast cancer (BC). The data showed that GnRH agonist use during chemotherapy was safe and effective to preserve ovarian function in these...

Read More

Evaluating the effectiveness and safety of camrelizumab in combination with XELOX chemotherapy plus bevacizumab or regorafenib in patients with advanced colorectal cancer.

Evaluating the effectiveness and safety of camrelizumab in combination with XELOX chemotherapy plus bevacizumab or regorafenib in patients with advanced colorectal cancer.

Posted by on Jan 30, 2022 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of camrelizumab (SHR1210) in combination with XELOX (capecitabine and oxaliplatin) chemotherapy plus bevacizumab (Avastin) or regorafenib (Stivarga) as first-line therapy in patients with metastatic colorectal cancer (mCRC). The data showed that the combination was effective for these...

Read More

Evaluating the effectiveness and safety of combining proton plus carbon-ion radiotherapy with chemotherapy given at the same time in patients with limited-stage small-cell lung cancer.

Evaluating the effectiveness and safety of combining proton plus carbon-ion radiotherapy with chemotherapy given at the same time in patients with limited-stage small-cell lung cancer.

Posted by on Jan 23, 2022 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of combining proton radiotherapy (PRT) plus carbon-ion radiotherapy (CIRT) with chemotherapy (CT) given at the same time in patients with limited-stage (LS) small cell lung cancer (SCLC). The data showed that PRT plus CIRT with CT given at the same time was effective with manageable side...

Read More

Evaluating the effectiveness and safety of radiotherapy for the treatment of patients with painless non-Hodgkin lymphoma.

Evaluating the effectiveness and safety of radiotherapy for the treatment of patients with painless non-Hodgkin lymphoma.

Posted by on Jan 23, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of radiotherapy (RT) for the treatment of patients with indolent (painless) non-Hodgkin lymphoma (iNHL). The data showed that RT was highly effective with manageable side effects in these patients. Some background Non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells...

Read More

How useful is bortezomib maintenance after allogeneic stem cell transplant in young or high-risk patients with multiple myeloma?

How useful is bortezomib maintenance after allogeneic stem cell transplant in young or high-risk patients with multiple myeloma?

Posted by on Jan 23, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the use of bortezomib (BTZ; Velcade) maintenance after allogeneic hematopoietic cell transplant (alloHCT) for improving relapse and chronic graft versus host disease (cGVHD) in patients with multiple myeloma (MM) that are young or high-risk. The data showed that BTZ maintenance is effective and safe in...

Read More

Clofarabine-fludarabine-busulfan conditioning before hematopoietic stem cell therapy in children with acute leukemia

Clofarabine-fludarabine-busulfan conditioning before hematopoietic stem cell therapy in children with acute leukemia

Posted by on Jan 23, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the combination of clofarabine (Clolar)-fludarabine (Fludara)-busulfan (Busulfex) as a conditioning regime in hematopoietic stem cell transplant (HSCT) for children with acute leukemia.  This study concluded that this combination is safe and effective in these patients.   Some...

Read More